NasdaqGS - Nasdaq Real Time Price USD

Ventyx Biosciences, Inc. (VTYX)

1.2400

+0.0700

+(5.98%)

At close: May 9 at 4:00:00 PM EDT

1.2799

+0.04

+(3.22%)

After hours: May 9 at 6:33:27 PM EDT

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson’s disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) --

GlobeNewswire 2 days ago

VTYX
+5.98%
Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

Key Insights Given the large stake in the stock by institutions, Ventyx Biosciences' stock price might be vulnerable to...

Simply Wall St. 6 days ago

VTYX
+5.98%
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program--AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-rec

GlobeNewswire last month

VTYX
+5.98%
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2VTX3232 in participants with obesity and cardiometabolic risk factors in H2VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: V

GlobeNewswire 2 months ago

VTYX
+5.98%
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patien

GlobeNewswire 2 months ago

VTYX
+5.98%
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceLocation: VirtualDate: We

GlobeNewswire 3 months ago

VTYX
+5.98%
Ventyx Biosciences highlights its 2025 pipeline strategy

Ventyx Biosciences (VTYX) highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025; Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025; Topline data from ongoing Phase 2 biomarker tr

TipRanks 3 months ago

VTYX
+5.98%
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with recurrent pericarditis expected to initiate in January, with topline data expected in H2 2025 Topline data from ongoing Phase 2 biomarker trial of VTX3232 in participants with early Parkinson’s disease expected in H1 2025 Cash, cash equivalents and marketable securities balance of $252.9M as of Decemb

GlobeNewswire 3 months ago

VTYX
+5.98%
We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 3 months ago

VTYX
+5.98%
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Insiders who bought Ventyx Biosciences, Inc. ( NASDAQ:VTYX ) in the last 12 months may probably not pay attention to...

Simply Wall St. 4 months ago

VTYX
+5.98%
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Key Insights Significantly high institutional ownership implies Ventyx Biosciences' stock price is sensitive to their...

Simply Wall St. 5 months ago

VTYX
+5.98%
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

Ventyx Biosciences, Inc. ( (VTYX) ) has released its Q3 earnings. Here is a breakdown of the information Ventyx Biosciences, Inc. presented to its investors. Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focusing on the development of novel oral therapies for autoimmune and inflammatory disorders, aiming to transition treatments from injectable to oral formats. In its latest earnings report for the third quarter of 2024, Ventyx Biosciences

TipRanks 5 months ago

VTYX
+5.98%
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: •Event: Stifel 2024 Healthcare Conference Location: New York, NY Date: Monday, November 18, 2024 Time: 4:10-4:40

GlobeNewswire 5 months ago

VTYX
+5.98%
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025 Phase 2 trial of VTX2735 in patients with recurrent pericarditis expected to initiate by year-end, with topline results anticipated in H2 2025 Cash balance of $274.8M as of September 30, 2024 expected to fund operations into

GlobeNewswire 5 months ago

VTYX
+5.98%
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts

In his iconic song The Gambler, Kenny Rogers famously sang, “Every hand’s a winner, and every hand’s a loser.” This line offers valuable wisdom for investors: no matter the strategy, success in the stock market ultimately depends on how well you navigate the balance between risk and reward. Few corners of the stock market present a greater potential return for the risk than penny stocks, which trade at $5 or less. These ultra-low-priced equities offer an attractive entry point for investors look

TipRanks 6 months ago

VTYX
+5.98%

RGLS
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

Late-breaking abstract highlights high rates of clinical and endoscopic remission among LTE completers at Week 52SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of

GlobeNewswire 6 months ago

VTYX
+5.98%
VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.

Zacks 7 months ago

VTYX
+5.98%

SNY
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.

Pharmaceutical Technology 7 months ago

SNY

VTYX
+5.98%
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted pric

GlobeNewswire 7 months ago

VTYX
+5.98%
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Results from this trial are expected in 2025SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease. “We are excited to initiate this trial of VTX3232 in pa

GlobeNewswire 7 months ago

VTYX
+5.98%

Performance Overview

Return	VTYX	S&P 500 (^GSPC)
YTD	-43.38%	-3.77%
1-Year	-72.32%	+8.55%
3-Year	-91.65%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ventyx Biosciences, Inc. (VTYX)

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Great week for Ventyx Biosciences, Inc. (NASDAQ:VTYX) institutional investors after losing 70% over the previous year

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences highlights its 2025 pipeline strategy

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts

Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024

VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Performance Overview